Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

BioNTech and InstaDeep use AI to predict high-risk SARS-CoV-2 variants 

By Brian Buntz | January 12, 2022

BioNTech/InstaDeepBioNTech (NSDQ:BNTX) and the enterprise AI company InstaDeep have announced that they have created an early warning system to improve the monitoring of potentially dangerous SARS-CoV-2 variants.

The companies claim that the system spotted more than 90% of WHO-designated variants an average of two months before the organization officially classified them. For example, the system classified the omicron variant as “high risk” on the same day its sequence was released.

BioNTech and InstaDeep plan on publishing the research in a peer-reviewed journal. The study is currently available as a pre-print. The paper notes that hundreds of new variants emerge daily, but most do not significantly alter the course of the pandemic.

The AI system considers the structure of the viral variants’ spike protein and their immune escape proclivity.

The two companies used in-house experimental data and public data to test the system’s accuracy.

Dr. Ugur Sahin, CEO of BioNTech, anticipates that the system could give vaccine developers and health authorities a headstart in responding to a high-risk variant.

“More than 10,000 novel variant sequences are currently discovered every week, and human experts simply cannot cope with complex data at this scale,” said Karim Beguir, co-founder and CEO of InstaDeep, in a statement.


Filed Under: Data science
Tagged With: BioNTech, coronavirus, covid-19, InstaDeep
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

FDA’s genAI push could save CDER hundreds of thousands of review hours annually
Elsevier plugs 500,000 ClinicalTrials.gov records into Embase
Transparent padlock, digital security concept, glowing background. AI generated
The challenge of AI inventorship in healthcare
From Graz to global — Innophore’s journey with NVIDIA’s BioNeMo
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE